Statera Biopharma, Inc. (NASDAQ:STAB – Get Rating) saw a large decline in short interest in March. As of March 31st, there was short interest totalling 154,000 shares, a decline of 28.3% from the March 15th total of 214,900 shares. Based on an average trading volume of 1,850,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.4% of the company’s shares are short sold.
NASDAQ STAB opened at $0.31 on Friday. The company has a fifty day simple moving average of $0.58 and a 200 day simple moving average of $1.82. Statera Biopharma has a 12-month low of $0.25 and a 12-month high of $7.10. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.31 and a quick ratio of 1.31.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James Financial Services Advisors Inc. acquired a new stake in Statera Biopharma in the 3rd quarter valued at $28,000. Dowling & Yahnke LLC acquired a new stake in Statera Biopharma in the 3rd quarter valued at $34,000. BlackRock Inc. acquired a new stake in Statera Biopharma in the 3rd quarter valued at $44,000. UBS Group AG acquired a new stake in Statera Biopharma in the 3rd quarter valued at $45,000. Finally, Virtu Financial LLC grew its position in Statera Biopharma by 134.8% in the 4th quarter. Virtu Financial LLC now owns 30,963 shares of the company’s stock valued at $71,000 after purchasing an additional 17,778 shares during the period. 4.57% of the stock is owned by institutional investors and hedge funds.
Statera BioPharma, Inc, a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers.
- Get a free copy of the StockNews.com research report on Statera Biopharma (STAB)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
Receive News & Ratings for Statera Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Statera Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.